ABVX vs PAYP Comparison

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

PayPay Corp is a FinTech company in Japan that operates a digital finance platform centered on payments, offering a range of payment and financial services to users and merchants. The company has two reportable segments: i) Payment segment: It includes payment settlement services and related services through its PayPay app, and credit payment settlement services such as revolving and installment payment options and cash advances; and ii) Financial service segment: It includes internet banking services, securities intermediary services and PayPay Point investment-related services, and loan management services. The majority of revenue is derived from the Payment segment. Geographically, the company's maximum revenue is generated in Japan.